Z-Thr-OBzl | 16597-50-5

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 苏氨酸类衍生物
• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Z-Thr-OBzl
• 英文别名: benzyl (2S)-3-hydroxy-2-(phenylmethoxycarbonylamino)butanoate
• CAS: 16597-50-5；84500-41-4；85995-50-2；85995-51-3；126401-06-7
• 化学式: C₁₉H₂₁NO₅
• 分子量: 343.379
• InChiKey: VBKUVUJWFDXTMS-JRZJBTRGSA-N

物化性质

• 熔点：
  78-82°C
• 沸点：
  536.8±50.0 °C(Predicted)
• 密度：
  1.228±0.06 g/cm3(Predicted)
• 溶解度：
  溶于氯仿、二氯甲烷、乙酸乙酯、DMSO、丙酮等。

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  25
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.26
• 拓扑面积：
  84.9
• 氢给体数：
  2
• 氢受体数：
  5

安全信息

• 安全说明：
  S24/25,S26,S36
• 海关编码：
  2924299090
• 危险品标志：
  Xi
• 危险类别码：
  R36/37/38
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

反应信息

• 作为反应物：
  描述：

  Z-Thr-OBzl 在 四氮唑 、 间氯过氧苯甲酸 作用下， 生成 (S)-2-Benzyloxycarbonylamino-3-(bis-allyloxy-phosphoryloxy)-butyric acid benzyl ester
  参考文献：
  名称：

  Bis(allyloxy)(diisopropylamino)phosphine as a new phosphinylation reagent for the phosphorylation of hydroxy functions

  摘要：

  DOI：

  10.1016/s0040-4039(01)80694-8

文献信息

• SUBSTITUTED OXOPYRIDINE DERIVATIVES
  申请人：BAYER PHARMA AKTIENGESELLSCHAFT

  公开号：US20180346424A1

  公开（公告）日：2018-12-06

  The invention relates to substituted oxopyridine derivatives and to processes for preparation thereof, and also to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of cardiovascular disorders, preferably thrombotic or thromboembolic disorders, and oedemas, and also ophthalmic disorders.

  这项发明涉及替代的氧代吡啶衍生物及其制备方法，以及用于制备治疗和/或预防疾病的药物的用途，特别是心血管疾病，尤其是血栓性或血栓栓塞性疾病，水肿，以及眼科疾病。
• Formation of DPM ethers using O-diphenylmethyl trichloroacetimidate under thermal conditions
  作者：Kyle T. Howard、Brian C. Duffy、Matthew R. Linaburg、John D. Chisholm

  DOI：10.1039/c5ob02455b

  日期：——

  diphenylmethyl (DPM) ethers by reaction with O-diphenylmethyl trichloroacetimidate in refluxing toluene without the requirement of a catalyst or other additives. A number of acid and base sensitive substrates were protected in excellent yield using this new method without disturbing the pre-existing functionality present in these molecules. This reaction is the first example of the formation of an ether from stoichiometric

  在不需要催化剂或其他添加剂的情况下，通过在回流的甲苯中与O-二苯基甲基三氯乙亚氨酸酯反应，可以将醇有效地转化为其相应的二苯基甲基（DPM）醚。使用这种新方法，许多酸和碱敏感的底物都得到了优异的保护，而不会干扰这些分子中预先存在的功能。该反应是在不添加布朗斯台德或路易斯酸催化剂的情况下由化学计量的三氯乙酰亚胺酸酯和醇形成醚的第一个例子。
• Novel compounds with high therapeutic index
  申请人：Chandran Ravi V.

  公开号：US20060241017A1

  公开（公告）日：2006-10-26

  The present invention is directed to novel therapeutic compounds comprised of an amino acid bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. These high therapeutic index derivatives have the same utility as the drug from which they are made, and they have enhanced pharmacological and pharmaceutical properties. In fact, the novel drug derivatives of the present invention enhance at least one therapeutic quality, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

  本发明涉及一种新型治疗化合物，其由氨基酸与具有羟基、氨基、羧基或酰化衍生物的药物或药物结合而成。这些高治疗指数的衍生物与它们所制备的药物具有相同的效用，并且它们具有增强的药理和制药特性。实际上，本发明的新型药物衍生物增强了至少一种治疗品质，如本文所定义。本发明还涉及含有这些化合物的制药组合物。
• L-THREONINE DERIVATIVES OF HIGH THERAPEUTIC INDEX
  申请人：Chandran V. Ravi

  公开号：US20100004481A1

  公开（公告）日：2010-01-07

  The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

  本发明涉及一种衍生物，其由L-苏氨酸与具有羟基、氨基、羧基或酰化衍生物的药物或药物结合而成。该衍生物具有与其制成的药物相同的功效，但具有增强的治疗性能。实际上，本发明的衍生物增强了至少一种或多种治疗特性，如本文所定义。本发明还涉及含有该衍生物的制药组合物。
• L-Threonine derivatives of high therapeutic index
  申请人：Chandran Ravi V.

  公开号：US20060287244A1

  公开（公告）日：2006-12-21

  The present invention is directed to a derivative comprised of an L-Threonine bonded to a medicament or drug having a hydroxy, amino, carboxy or acylating derivative thereon. The derivative has the same utility as the drug from which it is made, but it has enhanced therapeutic properties. In fact, the derivatives of the present invention enhance at least one or more therapeutic qualities, as defined herein. The present invention is also directed to pharmaceutical compositions containing same.

  本发明涉及一种衍生物，其由L-苏氨酸与具有羟基、氨基、羧基或酰化衍生物的药物或药物结合而成。该衍生物具有与其制成的药物相同的功效，但具有增强的治疗性能。事实上，本发明的衍生物增强了至少一种或多种治疗特性，如本文所定义。本发明还涉及含有该衍生物的制药组合物。